Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Weinberg A, Lambert SL, Canniff J, Yu L, Lang N, Esser MT, Falloon J, Levin MJ.

Hum Vaccin Immunother. 2019;15(10):2466-2474. doi: 10.1080/21645515.2019.1589282. Epub 2019 Jun 3.

PMID:
30852939
2.

Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults.

Lingblom CMD, Kowli S, Swaminathan N, Maecker HT, Lambert SL.

J Transl Med. 2018 Jun 5;16(1):153. doi: 10.1186/s12967-018-1528-1.

3.

Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay.

Shambaugh C, Azshirvani S, Yu L, Pache J, Lambert SL, Zuo F, Esser MT.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00225-17. doi: 10.1128/CVI.00225-17. Print 2017 Dec.

4.

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.

Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.

5.

Fetal-Type Variants of the Posterior Cerebral Artery and Concurrent Infarction in the Major Arterial Territories of the Cerebral Hemisphere.

Lambert SL, Williams FJ, Oganisyan ZZ, Branch LA, Mader EC Jr.

J Investig Med High Impact Case Rep. 2016 Sep 13;4(3):2324709616665409. doi: 10.1177/2324709616665409. eCollection 2016 Jul-Sep.

6.

Severe West Nile virus meningoencephalitis in a pediatric renal transplant recipient: successful recovery and long-term neuropsychological outcome.

Lambert SL, Aviles D, Vehaskari VM, Ashoor IF.

Pediatr Transplant. 2016 Sep;20(6):836-9. doi: 10.1111/petr.12768. Epub 2016 Jul 28.

PMID:
27470315
7.

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.

Patton K, Aslam S, Shambaugh C, Lin R, Heeke D, Frantz C, Zuo F, Esser MT, Paliard X, Lambert SL.

Vaccine. 2015 Aug 26;33(36):4472-8. doi: 10.1016/j.vaccine.2015.07.025. Epub 2015 Jul 20.

PMID:
26206269
8.

A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.

Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, Sweetwood R, Lei YM, Woo JC, Tang RS.

PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015.

9.

Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.

Hatton O, Lambert SL, Phillips LK, Vaysberg M, Natkunam Y, Esquivel CO, Krams SM, Martinez OM.

Am J Transplant. 2013 Apr;13(4):883-890. doi: 10.1111/ajt.12137. Epub 2013 Feb 7.

10.

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.

Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, Jin H, Woo J.

PLoS One. 2012;7(12):e51618. doi: 10.1371/journal.pone.0051618. Epub 2012 Dec 28.

11.

Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.

Hatton O, Lambert SL, Krams SM, Martinez OM.

PLoS One. 2012;7(8):e42610. doi: 10.1371/journal.pone.0042610. Epub 2012 Aug 3.

12.

Cross-national replication of the gender identity interview for children.

Wallien MS, Quilty LC, Steensma TD, Singh D, Lambert SL, Leroux A, Owen-Anderson A, Kibblewhite SJ, Bradley SJ, Cohen-Kettenis PT, Zucker KJ.

J Pers Assess. 2009 Nov;91(6):545-52. doi: 10.1080/00223890903228463.

PMID:
19838904
13.

Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma.

Vaysberg M, Lambert SL, Krams SM, Martinez OM.

Am J Transplant. 2009 Oct;9(10):2292-302. doi: 10.1111/j.1600-6143.2009.02781.x. Epub 2009 Jul 28.

14.

Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.

Vaysberg M, Hatton O, Lambert SL, Snow AL, Wong B, Krams SM, Martinez OM.

J Biol Chem. 2008 Dec 26;283(52):36573-85. doi: 10.1074/jbc.M802968200. Epub 2008 Nov 5.

15.
16.

EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.

Snow AL, Lambert SL, Natkunam Y, Esquivel CO, Krams SM, Martinez OM.

J Immunol. 2006 Sep 1;177(5):3283-93.

17.
18.

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas.

Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R.

Blood. 2001 Mar 1;97(5):1370-7.

PMID:
11222382

Supplemental Content

Loading ...
Support Center